# EDGAR Filing Document

**Accession Number:** 0001131343
**File Stem:** 0001213900-23-020408
**Filing Date:** 2023-3
**Character Count:** 5584
**Document Hash:** 8c311dae27d616f52a06aa4b7d39ed81
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001213900-23-020408.hdr.sgml**: 20230316

**ACCESSION NUMBER**: 0001213900-23-020408

**CONFORMED SUBMISSION TYPE**: 6-K

**PUBLIC DOCUMENT COUNT**: 3

**CONFORMED PERIOD OF REPORT**: 20230316

**FILED AS OF DATE**: 20230316

**DATE AS OF CHANGE**: 20230316

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** ALTERITY THERAPEUTICS LTD
- **CENTRAL INDEX KEY:** 0001131343
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 000000000
- **STATE OF INCORPORATION:** C3
- **FISCAL YEAR END:** 0630

**FILING VALUES:**
- **FORM TYPE:** 6-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 000-49843
- **FILM NUMBER:** 23737013

**BUSINESS ADDRESS:**
- **STREET 1:** LEVEL 3, 460 BOURKE STREET
- **CITY:** MELBOURNE
- **STATE:** C3
- **ZIP:** VIC 3000
- **BUSINESS PHONE:** 61 3 9349 4906

**MAIL ADDRESS:**
- **STREET 1:** LEVEL 3, 460 BOURKE STREET
- **CITY:** MELBOURNE
- **STATE:** C3
- **ZIP:** VIC 3000

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** PRANA BIOTECHNOLOGY LTD
- **DATE OF NAME CHANGE:** 20010105

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 6-K**

**REPORT OF FOREIGN PRIVATE ISSUER**

**PURSUANT TO RULE 13a-16 OR 15d-163**

**UNDER THE SECURITIES EXCHANGE ACT OF 1934**

**For the month of March 2023**

**Alterity Therapeutics Limited**

(Name of Registrant)

**Level 3, 460 Bourke Street, Melbourne, VIC 3000, Australia**

(Address of Principal Executive Office)

**Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.**

Form 20-F ☒ Form 40-F ☐

**Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): __**

**Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): __**

**Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.**

Yes ☐ No ☒

**If "Yes" is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82- _____**

**This Form 6-K is being incorporated by reference into our Registration Statement on Form S-8 (Files No. [333-251073](http://www.sec.gov/Archives/edgar/data/1131343/000121390020040485/ea130838-s8_alteritytherape.htm), [333-248980](http://www.sec.gov/Archives/edgar/data/1131343/000121390020027969/ea127207-s8_alteritytherap.htm) and [333-228671](http://www.sec.gov/Archives/edgar/data/1131343/000114420418063081/tv508429_s-8.htm)) and our Registration Statements on Form F-3 (Files No. [333-251647](http://www.sec.gov/Archives/edgar/data/1131343/000121390020044324/ea132148-f3_alteritytherape.htm), [333-249311](http://www.sec.gov/Archives/edgar/data/1131343/000121390020030109/ea127808-f3_alterityther.htm), [333-231417](http://www.sec.gov/Archives/edgar/data/1131343/000114420419025615/tv521271_f3.htm) and [333-250076](http://www.sec.gov/Archives/edgar/data/1131343/000121390020036934/ea129831-f3_alteritytherap.htm))**

ALTERITY THERAPEUTICS LIMITED

(a development stage enterprise)

The following exhibits are submitted:

99.1 [Notice Under Section 708A](ea175319ex99-1_alterity.htm)

**<u>SIGNATURE</u>**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

---

| | |
|:---|:---|
| **Alterity Therapeutics Limited** | **Alterity Therapeutics Limited** |
| /s/ Geoffrey P. Kempler | /s/ Geoffrey P. Kempler |
| By: | Geoffrey P. Kempler |
|  | Chairman |

---

Date: March 16, 2023

## Exhibit 99.1

**Exhibit 99.1**

![](ex99-1_001.jpg)

---

| | |
|:---|:---|
| **ASX ANNOUNCEMENT** | 16 March 2023 |

---

**Notice Under Section 708A(5)(e) of the Corporations Act**

This notice is given by Alterity Therapeutics Limited ACN 080 699 065 (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), under section 708A(5)(e) of the Corporations Act 2001 (Cth) (Corporations Act).

**Details of securities issued**

---

| | |
|:---|:---|
| &nbsp;&nbsp;**Type** | &nbsp;&nbsp;**Shares** |
| &nbsp;&nbsp;Class/Description | &nbsp;&nbsp;Fully paid ordinary shares |
| &nbsp;&nbsp;ASX Code | &nbsp;&nbsp;ATH |
| &nbsp;&nbsp;Date of Issue | &nbsp;&nbsp;15 March 2023 |
| &nbsp;&nbsp;Number Issued | &nbsp;&nbsp;23479200 |
| &nbsp;&nbsp;Issue Price per Security | &nbsp;&nbsp;AUD 0.0076 |

---

The Company gives notice pursuant to section 708A(5)(e) of the Corporations Act that:

&nbsp;&nbsp;&nbsp;&nbsp;1. the Company issued the Shares without disclosure under Part 6D.2 of the Corporations Act;

&nbsp;&nbsp;&nbsp;&nbsp;2. as at the date of this notice, the Company has complied with:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) the provisions of Chapter 2M of the Corporations Act as they
apply to the Company; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) sections 674 and 674A of the Corporations Act; and

&nbsp;&nbsp;&nbsp;&nbsp;3. as at the date of this notice there is no information to be disclosed which is 'excluded information'
(as defined in sections 708A(7) and 708A(8) of the Corporations Act) which is required to be disclosed by the Company.

**Phillip Hains<br> Company Secretary**

Alterity Therapeutics Limited ACN 080 699 065

Level 3, 62 Lygon Street Carlton Victoria 3053 Australia

www.alteritytherapeutics.com